GSK Pharma posts Q4 PAT of Rs103.59 crore

Glaxosmithkline Pharma reported fourth quarter results that were in line with market expectations, with the company, which is in the top league in the domestic market, posting an improved performance across all the business segments of mass market, mass specialty, specialty segments and vaccines.

The company reported a profit after tax (PAT) of Rs103.59 crore as against Rs 208.47 crore. Revenues were up 20 per cent at Rs449.9 crore from Rs375.24 crore and operating profit margin (OPM) increased to 32 per cent as against 29.7 per cent.

In Q4CY08, the reported an exceptional inflow of Rs119.31 crore

Revenues also increased and OPM expanded even as total expenditure rose 16 per cent to Rs306.04 crore.
Other income was lower 35 per cent at Rs19.47 crore and exceptional outflow stood at Rs3.13 crore.

For CY09, the company's consolidated revenue was up 12.5 per cent to Rs1,926.5 crore from Rs1,712.5 crore. With OPM flat at 36 per cent PAT declined to Rs507.86 crore as against Rs591.09 crore.

The company reported a nearly 20 per cent growth in net sales with a low base year effect partly contributing to the higher-than-expected growth in sales. The market reaction was neutral to the results as the stock closed flat at Rs1,577.